Tackling Burkitt when it's back

摘要

In this issue of Blood, Woessmann et al report on outcomes of 157 children with refractory or relapsed Burkitt lymphoma (BL) or Burkitt leukemia (B-AL) who were included in non-Hodgkin lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) studies over a 30-year period.(1) Despite various aggressive strategies, survival in the group that did not achieve remission with primary therapy remains distressingly low.